Your browser doesn't support javascript.
loading
Applicability and performance of 18F-FDG PET-based modalities for whole-body cancer screening: a systematic review and meta-analysis.
Das, K J; Meena, J K; Kumar, D.
Affiliation
  • Das KJ; Dept. of Nuclear Medicine, National Cancer Institute (NCI-AIIMS), All India Institute of Medical Sciences (AIIMS), New Delhi, India.
  • Meena JK; Dept. of Preventive Oncology, National Cancer Institute (NCI-AIIMS), All India Institute of Medical Sciences (AIIMS), New Delhi, India. drmeenajk@gmail.com.
  • Kumar D; Dept. of Nuclear Medicine, Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, India.
Jpn J Radiol ; 2024 Sep 20.
Article in En | MEDLINE | ID: mdl-39302525
ABSTRACT

PURPOSE:

Screening tests are the cornerstone for early detection and optimal management of cancers. Most of the present cancer-screening tests are intrusive, time-consuming, and specifically target a particular anatomical site or cancer type. Only a few studies have reported the objective measures of 18F-FDG PET-based cancer screening in asymptomatic individuals. This review and meta-analysis is an attempt to assess the applicability and performance of 18F-FDG PET-based modalities for whole-body cancer screening. MATERIALS AND

METHODS:

The systematic review and meta-analysis were performed following PRISMA guidelines. Literature searches in PubMed, Scopus, and Embase were conducted using relevant MeSH terms and keywords, for articles published in the last 2 decades (2000-2022). Pooled estimates of diagnostic test accuracy-including sensitivity, specificity, positive-likelihood ratio, negative-likelihood ratio, and hierarchical summary ROC (HSROC) curve were generated using bivariate random-effects meta-analysis.

RESULTS:

Seventeen studies were included in the systematic review and 13 studies were deemed eligible for meta-analysis. The mean estimates of pooled sensitivity, specificity, positive-likelihood ratio, negative-likelihood ratio, and Odds ratio using 18F-FDG PET with a 95% confidence interval were 0.47 (0.25-0.69), 0.97 (0.95-0.98), 18.8 (6.8-51.5), 0.45 (0.27-0.76), 41.0 (7.9-211.8) and for 18F-FDG PET/CT were 0.83 (0.75-0.88), 0.98 (0.97-0.99), 49.7 (29.2-84.5), 0.15 (0.8-0.28), 329.9 (125.0-870.8), respectively. Among screening modalities, 18F-FDG PET/CT had a higher accuracy i.e., the area under the HSROC curve (AUC) 0.91 (0.87-0.95) compared to 18F-FDG PET 0.72 (0.61-0.82).

CONCLUSION:

This study demonstrates that currently 18F-FDG PET-based screening has limited applicability for population-based cancer-screening programs. However, it has a promising role as a combined screening strategy for at-risk individuals and allows for comprehensive diagnostic and prognostic evaluation in high-resource settings.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Jpn J Radiol Journal subject: DIAGNOSTICO POR IMAGEM / RADIOLOGIA / RADIOTERAPIA Year: 2024 Document type: Article Affiliation country: India Country of publication: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Jpn J Radiol Journal subject: DIAGNOSTICO POR IMAGEM / RADIOLOGIA / RADIOTERAPIA Year: 2024 Document type: Article Affiliation country: India Country of publication: Japan